Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 418

1.

A multiparametric magnetic resonance imaging-based virtual reality surgical navigation tool for robotic-assisted radical prostatectomy.

Mehralivand S, Kolagunda A, Hammerich K, Sabarwal V, Harmon S, Sanford T, Gold S, Hale G, Romero VV, Bloom J, Merino MJ, Wood BJ, Kambhamettu C, Choyke PL, Pinto PA, Türkbey B.

Turk J Urol. 2019 Sep 1;45(5):357-365. doi: 10.5152/tud.2019.19133.

2.

Apical periurethral transition zone lesions: MRI and histology findings.

Tuncer S, Mehralivand S, Harmon SA, Sanford T, Brown GT, Rowe LS, Merino MJ, Wood BJ, Pinto PA, Choyke PL, Turkbey B.

Abdom Radiol (NY). 2019 Aug 29. doi: 10.1007/s00261-019-02194-x. [Epub ahead of print]

PMID:
31468153
3.

Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights.

Carlo MI, Hakimi AA, Stewart GD, Bratslavsky G, Brugarolas J, Chen YB, Linehan WM, Maher ER, Merino MJ, Offit K, Reuter VE, Shuch B, Coleman JA.

Eur Urol. 2019 Jul 17. pii: S0302-2838(19)30500-7. doi: 10.1016/j.eururo.2019.06.015. [Epub ahead of print] Review.

PMID:
31326218
4.

Use of multiparametric magnetic resonance imaging and fusion-guided biopsies to properly select and follow African-American men on active surveillance.

Bloom JB, Lebastchi AH, Gold SA, Hale GR, Sanford T, Mehralivand S, Ahdoot M, Rayn KN, Czarniecki M, Smith C, Valera V, Wood BJ, Merino MJ, Choyke PL, Parnes HL, Turkbey B, Pinto PA.

BJU Int. 2019 May 29. doi: 10.1111/bju.14835. [Epub ahead of print]

PMID:
31141307
5.

mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy.

Gold SA, VanderWeele DJ, Harmon S, Bloom JB, Karzai F, Hale GR, Marhamati S, Rayn KN, Mehralivand S, Merino MJ, Gulley JL, Bilusic M, Madan RA, Choyke PL, Turkbey B, Dahut W, Pinto PA.

Urol Oncol. 2019 Jun;37(6):352.e25-352.e30. doi: 10.1016/j.urolonc.2019.01.012. Epub 2019 Apr 15.

PMID:
31000430
6.

Interreader Variability of Prostate Imaging Reporting and Data System Version 2 in Detecting and Assessing Prostate Cancer Lesions at Prostate MRI.

Greer MD, Shih JH, Lay N, Barrett T, Bittencourt L, Borofsky S, Kabakus I, Law YM, Marko J, Shebel H, Merino MJ, Wood BJ, Pinto PA, Summers RM, Choyke PL, Turkbey B.

AJR Am J Roentgenol. 2019 Mar 27:1-8. doi: 10.2214/AJR.18.20536. [Epub ahead of print]

PMID:
30917023
7.

First-in-human phase 0 study of 111In-CHX-A"-DTPA trastuzumab for HER2 tumor imaging.

Kurdziel KA, Mena E, McKinney Y, Wong K, Adler S, Sissung T, Lee J, Lipkowitz S, Lindenberg L, Turkbey B, Kummar S, Milenic DE, Doroshow JH, Figg WD, Merino MJ, Paik CH, Brechbiel MW, Choyke PL.

J Transl Sci. 2019 Apr;5(2). doi: 10.15761/JTS.1000269. Epub 2018 Jul 13.

8.

A Grading System for the Assessment of Risk of Extraprostatic Extension of Prostate Cancer at Multiparametric MRI.

Mehralivand S, Shih JH, Harmon S, Smith C, Bloom J, Czarniecki M, Gold S, Hale G, Rayn K, Merino MJ, Wood BJ, Pinto PA, Choyke PL, Turkbey B.

Radiology. 2019 Mar;290(3):709-719. doi: 10.1148/radiol.2018181278. Epub 2019 Jan 22.

PMID:
30667329
9.

Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: Role of a Negative Confirmatory Magnetic Resonance Imaging-Ultrasound Fusion Biopsy.

Bloom JB, Hale GR, Gold SA, Rayn KN, Smith C, Mehralivand S, Czarniecki M, Valera V, Wood BJ, Merino MJ, Choyke PL, Parnes HL, Turkbey B, Pinto PA.

J Urol. 2019 Jan;201(1):84-90. doi: 10.1016/j.juro.2018.07.051.

PMID:
30577395
10.

Germline mutations of renal cancer predisposition genes and clinical relevance in Chinese patients with sporadic, early-onset disease.

Wu J, Wang H, Ricketts CJ, Yang Y, Merino MJ, Zhang H, Shi G, Gan H, Linehan WM, Zhu Y, Ye D.

Cancer. 2019 Apr 1;125(7):1060-1069. doi: 10.1002/cncr.31908. Epub 2018 Dec 12.

PMID:
30548481
11.

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.

Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A, Couvillon A, Nichols E, Bilusic M, Beshiri ML, Kelly K, Krishnasamy V, Lee S, Lee MJ, Yuno A, Trepel JB, Merino MJ, Dittamore R, Marté J, Donahue RN, Schlom J, Killian KJ, Meltzer PS, Steinberg SM, Gulley JL, Lee JM, Dahut WL.

J Immunother Cancer. 2018 Dec 4;6(1):141. doi: 10.1186/s40425-018-0463-2.

12.

CDC73 Germline Mutation in a Family With Mixed Epithelial and Stromal Tumors.

Vocke CD, Ricketts CJ, Ball MW, Schmidt LS, Metwalli AR, Middelton LA, Killian JK, Khan J, Meltzer PS, Simonds WF, Merino MJ, Linehan WM.

Urology. 2019 Feb;124:91-97. doi: 10.1016/j.urology.2018.11.013. Epub 2018 Nov 16.

13.

Do patients with familial nonmedullary thyroid cancer present with more aggressive disease? Implications for initial surgical treatment.

El Lakis M, Giannakou A, Nockel PJ, Wiseman D, Gara SK, Patel D, Sater ZA, Kushchayeva YY, Klubo-Gwiezdzinska J, Nilubol N, Merino MJ, Kebebew E.

Surgery. 2019 Jan;165(1):50-57. doi: 10.1016/j.surg.2018.05.075. Epub 2018 Oct 14.

14.

Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.

Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM.

Clin Genitourin Cancer. 2019 Feb;17(1):1-6. doi: 10.1016/j.clgc.2018.09.005. Epub 2018 Sep 12.

PMID:
30287223
15.

Incidental bladder cancers found on multiparametric MRI of the prostate gland: a single center experience.

Rayn KN, Hale GR, Bloom JB, Gold SA, Carvalho FLF, Mehralivand S, Czarniecki M, Wood BJ, Merino MJ, Choyke P, Türkbey B, Pinto PA, Agarwal PK.

Diagn Interv Radiol. 2018 Sep;24(5):316-320. doi: 10.5152/dir.2018.18102. Review.

16.

Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: Role of a Negative Confirmatory Magnetic Resonance Imaging-Ultrasound Fusion Biopsy.

Bloom JB, Hale GR, Gold SA, Rayn KN, Smith C, Mehralivand S, Czarniecki M, Valera V, Wood BJ, Merino MJ, Choyke PL, Parnes HL, Turkbey B, Pinto PA.

J Urol. 2019 Jan;201(1):84-90. doi: 10.1016/j.juro.2018.07.051.

PMID:
30063928
17.

Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy.

Feliz-Mosquea YR, Christensen AA, Wilson AS, Westwood B, Varagic J, Meléndez GC, Schwartz AL, Chen QR, Mathews Griner L, Guha R, Thomas CJ, Ferrer M, Merino MJ, Cook KL, Roberts DD, Soto-Pantoja DR.

Breast Cancer Res Treat. 2018 Nov;172(1):69-82. doi: 10.1007/s10549-018-4884-x. Epub 2018 Jul 28.

PMID:
30056566
18.

The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.

Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG; Cancer Genome Atlas Research Network, Spellman PT, Rathmell WK, Linehan WM.

Cell Rep. 2018 Jun 19;23(12):3698. doi: 10.1016/j.celrep.2018.06.032. No abstract available.

19.

Added Value of Multiparametric Magnetic Resonance Imaging to Clinical Nomograms for Predicting Adverse Pathology in Prostate Cancer.

Rayn KN, Bloom JB, Gold SA, Hale GR, Baiocco JA, Mehralivand S, Czarniecki M, Sabarwal VK, Valera V, Wood BJ, Merino MJ, Choyke P, Turkbey B, Pinto PA.

J Urol. 2018 Nov;200(5):1041-1047. doi: 10.1016/j.juro.2018.05.094. Epub 2018 May 29.

PMID:
29852182
20.

Validation of PI-RADS Version 2 in Transition Zone Lesions for the Detection of Prostate Cancer.

Thai JN, Narayanan HA, George AK, Siddiqui MM, Shah P, Mertan FV, Merino MJ, Pinto PA, Choyke PL, Wood BJ, Turkbey B.

Radiology. 2018 Aug;288(2):485-491. doi: 10.1148/radiol.2018170425. Epub 2018 May 22.

21.

Fusion prostate biopsy outperforms 12-core systematic prostate biopsy in patients with prior negative systematic biopsy: A multi-institutional analysis.

Sidana A, Watson MJ, George AK, Rastinehad AR, Vourganti S, Rais-Bahrami S, Muthigi A, Maruf M, Gordetsky JB, Nix JW, Merino MJ, Turkbey B, Choyke PL, Wood BJ, Pinto PA.

Urol Oncol. 2018 Jul;36(7):341.e1-341.e7. doi: 10.1016/j.urolonc.2018.04.002. Epub 2018 May 10.

PMID:
29753548
22.

Can Apparent Diffusion Coefficient Values Assist PI-RADS Version 2 DWI Scoring? A Correlation Study Using the PI-RADSv2 and International Society of Urological Pathology Systems.

Gaur S, Harmon S, Rosenblum L, Greer MD, Mehralivand S, Coskun M, Merino MJ, Wood BJ, Shih JH, Pinto PA, Choyke PL, Turkbey B.

AJR Am J Roentgenol. 2018 Jul;211(1):W33-W41. doi: 10.2214/AJR.17.18702. Epub 2018 May 7.

PMID:
29733695
23.

Morphological changes induced by intraprostatic PSA-based vaccine in prostate cancer biopsies (phase I clinical trial).

Merino MJ, Pinto PA, Moreno V, Gil S, Schlom J, Gulley JL.

Hum Pathol. 2018 Aug;78:72-78. doi: 10.1016/j.humpath.2018.04.013. Epub 2018 Apr 30.

PMID:
29709495
24.

A Multireader Exploratory Evaluation of Individual Pulse Sequence Cancer Detection on Prostate Multiparametric Magnetic Resonance Imaging (MRI).

Gaur S, Harmon S, Gupta RT, Margolis DJ, Lay N, Mehralivand S, Merino MJ, Wood BJ, Pinto PA, Shih JH, Choyke PL, Turkbey B.

Acad Radiol. 2019 Jan;26(1):5-14. doi: 10.1016/j.acra.2018.03.024. Epub 2018 Apr 25.

PMID:
29705281
25.

Computer-aided diagnosis prior to conventional interpretation of prostate mpMRI: an international multi-reader study.

Greer MD, Lay N, Shih JH, Barrett T, Bittencourt LK, Borofsky S, Kabakus I, Law YM, Marko J, Shebel H, Mertan FV, Merino MJ, Wood BJ, Pinto PA, Summers RM, Choyke PL, Turkbey B.

Eur Radiol. 2018 Oct;28(10):4407-4417. doi: 10.1007/s00330-018-5374-6. Epub 2018 Apr 12.

PMID:
29651763
26.

The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.

Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG; Cancer Genome Atlas Research Network, Spellman PT, Rathmell WK, Linehan WM.

Cell Rep. 2018 Apr 3;23(1):313-326.e5. doi: 10.1016/j.celrep.2018.03.075. Erratum in: Cell Rep. 2018 Jun 19;23(12):3698.

27.

Prospective comparison of PI-RADS version 2 and qualitative in-house categorization system in detection of prostate cancer.

Gaur S, Harmon S, Mehralivand S, Bednarova S, Calio BP, Sugano D, Sidana A, Merino MJ, Pinto PA, Wood BJ, Shih JH, Choyke PL, Turkbey B.

J Magn Reson Imaging. 2018 Nov;48(5):1326-1335. doi: 10.1002/jmri.26025. Epub 2018 Mar 31.

PMID:
29603833
28.

Germline VHL gene variant in patients with von Hippel-Lindau disease does not predict renal tumor growth.

Farhadi F, Nikpanah M, Li X, Symons R, Pourmorteza A, Merino MJ, Linehan WM, Malayeri AA.

Abdom Radiol (NY). 2018 Oct;43(10):2743-2749. doi: 10.1007/s00261-018-1540-1.

PMID:
29525880
29.

Differentiating papillary type I RCC from clear cell RCC and oncocytoma: application of whole-lesion volumetric ADC measurement.

Paschall AK, Mirmomen SM, Symons R, Pourmorteza A, Gautam R, Sahai A, Dwyer AJ, Merino MJ, Metwalli AR, Linehan WM, Malayeri AA.

Abdom Radiol (NY). 2018 Sep;43(9):2424-2430. doi: 10.1007/s00261-017-1453-4.

PMID:
29520425
30.

The Unknown microRNA Expression of Male Breast Cancer. Similarities and Differences with Female Ductal Carcinoma. Their Role as Tumor Biomarker.

Merino MJ, Gil S, Macias CG, Lara K.

J Cancer. 2018 Jan 1;9(3):450-459. doi: 10.7150/jca.23151. eCollection 2018.

31.

A Magnetic Resonance Imaging-Based Prediction Model for Prostate Biopsy Risk Stratification.

Mehralivand S, Shih JH, Rais-Bahrami S, Oto A, Bednarova S, Nix JW, Thomas JV, Gordetsky JB, Gaur S, Harmon SA, Siddiqui MM, Merino MJ, Parnes HL, Wood BJ, Pinto PA, Choyke PL, Turkbey B.

JAMA Oncol. 2018 May 1;4(5):678-685. doi: 10.1001/jamaoncol.2017.5667.

32.

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.

Lee JM, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ, Swisher EM, Harrell MI, Trepel JB, Lee MJ, Bagheri MH, Botesteanu DA, Steinberg SM, Minasian L, Ekwede I, Kohn EC.

Lancet Oncol. 2018 Feb;19(2):207-215. doi: 10.1016/S1470-2045(18)30009-3. Epub 2018 Jan 18.

PMID:
29361470
33.

All over the map: An interobserver agreement study of tumor location based on the PI-RADSv2 sector map.

Greer MD, Shih JH, Barrett T, Bednarova S, Kabakus I, Law YM, Shebel H, Merino MJ, Wood BJ, Pinto PA, Choyke PL, Turkbey B.

J Magn Reson Imaging. 2018 Aug;48(2):482-490. doi: 10.1002/jmri.25948. Epub 2018 Jan 17.

PMID:
29341356
34.

Multiparametric MRI for the detection of local recurrence of prostate cancer in the setting of biochemical recurrence after low dose rate brachytherapy.

Valle LF, Greer MD, Shih JH, Barrett T, Law YM, Rosenkrantz AB, Shebel H, Muthigi A, Su D, Merino MJ, Wood BJ, Pinto PA, Krauze AV, Kaushal A, Choyke PL, Türkbey B, Citrin DE.

Diagn Interv Radiol. 2018 Jan-Feb;24(1):46-53. doi: 10.5152/dir.2018.17285.

35.

CD38 knockout suppresses tumorigenesis in mice and clonogenic growth of human lung cancer cells.

Bu X, Kato J, Hong JA, Merino MJ, Schrump DS, Lund FE, Moss J.

Carcinogenesis. 2018 Feb 9;39(2):242-251. doi: 10.1093/carcin/bgx137.

36.

Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.

Kraft IL, Akshintala S, Zhu Y, Lei H, Derse-Anthony C, Dombi E, Steinberg SM, Lodish M, Waguespack SG, Kapustina O, Fox E, Balis FM, Merino MJ, Meltzer PS, Glod JW, Shern JF, Widemann BC.

Clin Cancer Res. 2018 Feb 15;24(4):753-765. doi: 10.1158/1078-0432.CCR-17-2101. Epub 2017 Nov 29.

37.

Risk of Upgrading from Prostate Biopsy to Radical Prostatectomy Pathology-Does Saturation Biopsy of Index Lesion during Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy Help?

Calio BP, Sidana A, Sugano D, Gaur S, Maruf M, Jain AL, Merino MJ, Choyke PL, Wood BJ, Pinto PA, Turkbey B.

J Urol. 2018 Apr;199(4):976-982. doi: 10.1016/j.juro.2017.10.048. Epub 2018 Jan 20.

PMID:
29154904
38.

What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate.

Borofsky S, George AK, Gaur S, Bernardo M, Greer MD, Mertan FV, Taffel M, Moreno V, Merino MJ, Wood BJ, Pinto PA, Choyke PL, Turkbey B.

Radiology. 2018 Jan;286(1):186-195. doi: 10.1148/radiol.2017152877. Epub 2017 Oct 20.

39.

The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.

Le Gallo M, Rudd ML, Urick ME, Hansen NF; National Institutes of Health Intramural Sequencing Center Comparative Sequencing Program, Merino MJ, Mutch DG, Goodfellow PJ, Mullikin JC, Bell DW.

Cancer. 2018 Jan 1;124(1):65-73. doi: 10.1002/cncr.30971. Epub 2017 Sep 21.

40.

Correlation between ERG Fusion Protein and Androgen Receptor Expression by Immunohistochemistry in Prostate, Possible Role in Diagnosis and Therapy.

Navaei AH, Walter BA, Moreno V, Pack SD, Pinto P, Merino MJ.

J Cancer. 2017 Aug 5;8(13):2604-2613. doi: 10.7150/jca.16751. eCollection 2017.

41.

Clinical impact of PSMA-based 18F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy.

Mena E, Lindenberg ML, Shih JH, Adler S, Harmon S, Bergvall E, Citrin D, Dahut W, Ton AT, McKinney Y, Weaver J, Eclarinal P, Forest A, Afari G, Bhattacharyya S, Mease RC, Merino MJ, Pinto P, Wood BJ, Jacobs P, Pomper MG, Choyke PL, Turkbey B.

Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):4-11. doi: 10.1007/s00259-017-3818-x. Epub 2017 Sep 11.

PMID:
28894899
42.

18F-DCFBC Prostate-Specific Membrane Antigen-Targeted PET/CT Imaging in Localized Prostate Cancer: Correlation With Multiparametric MRI and Histopathology.

Turkbey B, Mena E, Lindenberg L, Adler S, Bednarova S, Berman R, Ton AT, McKinney Y, Eclarinal P, Hill C, Afari G, Bhattacharyya S, Mease RC, Merino MJ, Jacobs PM, Wood BJ, Pinto PA, Pomper MG, Choyke PL.

Clin Nucl Med. 2017 Oct;42(10):735-740. doi: 10.1097/RLU.0000000000001804.

43.

Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276).

Yang Y, Vocke CD, Ricketts CJ, Wei D, Padilla-Nash HM, Lang M, Sourbier C, Killian JK, Boyle SL, Worrell R, Meltzer PS, Ried T, Merino MJ, Metwalli AR, Linehan WM.

Genes Chromosomes Cancer. 2017 Oct;56(10):719-729. doi: 10.1002/gcc.22476. Epub 2017 Jul 24.

44.

Validation of the Dominant Sequence Paradigm and Role of Dynamic Contrast-enhanced Imaging in PI-RADS Version 2.

Greer MD, Shih JH, Lay N, Barrett T, Kayat Bittencourt L, Borofsky S, Kabakus IM, Law YM, Marko J, Shebel H, Mertan FV, Merino MJ, Wood BJ, Pinto PA, Summers RM, Choyke PL, Turkbey B.

Radiology. 2017 Dec;285(3):859-869. doi: 10.1148/radiol.2017161316. Epub 2017 Jul 19.

45.

Results of Screening in Familial Non-Medullary Thyroid Cancer.

Klubo-Gwiezdzinska J, Yang L, Merkel R, Patel D, Nilubol N, Merino MJ, Skarulis M, Sadowski SM, Kebebew E.

Thyroid. 2017 Aug;27(8):1017-1024. doi: 10.1089/thy.2016.0668. Epub 2017 Jul 19.

46.

Multiple Recurrent Paraganglioma in a Pediatric Patient with Germline SDH-B Mutation.

McGowan A, An JY, Tanakchi S, Maruf M, Muthigi A, George A, Su D, Merino MJ, Linehan WM, Boyle SL, Metwalli AR.

Urol Case Rep. 2017 Apr 27;13:107-109. doi: 10.1016/j.eucr.2017.03.017. eCollection 2017 Jul.

47.

Prospective Evaluation of PI-RADS™ Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System.

Mehralivand S, Bednarova S, Shih JH, Mertan FV, Gaur S, Merino MJ, Wood BJ, Pinto PA, Choyke PL, Turkbey B.

J Urol. 2017 Sep;198(3):583-590. doi: 10.1016/j.juro.2017.03.131. Epub 2017 Mar 31.

PMID:
28373133
48.

Comprehensive genomic and phenotypic characterization of germline FH deletion in hereditary leiomyomatosis and renal cell carcinoma.

Vocke CD, Ricketts CJ, Merino MJ, Srinivasan R, Metwalli AR, Middelton LA, Peterson J, Yang Y, Linehan WM.

Genes Chromosomes Cancer. 2017 Jun;56(6):484-492. doi: 10.1002/gcc.22452. Epub 2017 Mar 31.

49.

RARRES2 functions as a tumor suppressor by promoting β-catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma.

Liu-Chittenden Y, Jain M, Gaskins K, Wang S, Merino MJ, Kotian S, Kumar Gara S, Davis S, Zhang L, Kebebew E.

Oncogene. 2017 Jun 22;36(25):3541-3552. doi: 10.1038/onc.2016.497. Epub 2017 Jan 23.

50.

H255Y and K508R missense mutations in tumour suppressor folliculin (FLCN) promote kidney cell proliferation.

Hasumi H, Hasumi Y, Baba M, Nishi H, Furuya M, Vocke CD, Lang M, Irie N, Esumi C, Merino MJ, Kawahara T, Isono Y, Makiyama K, Warner AC, Haines DC, Wei MH, Zbar B, Hagenau H, Feigenbaum L, Kondo K, Nakaigawa N, Yao M, Metwalli AR, Marston Linehan W, Schmidt LS.

Hum Mol Genet. 2017 Jan 15;26(2):354-366. doi: 10.1093/hmg/ddw392.

Supplemental Content

Loading ...
Support Center